{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:14:38Z","timestamp":1789463678700,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.nucmedbio.2010.02.009","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T03:22:40Z","timestamp":1271042560000},"page":"539-546","source":"Crossref","is-referenced-by-count":40,"title":["Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine"],"prefix":"10.1016","volume":"37","author":[{"given":"Sara","family":"Ahlgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofer","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2010.02.009_bib1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.2001.19.6.1865","article-title":"American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Bast","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","article-title":"Tumor markers in breast cancer- European Group on Tumor Markers recommendations","volume":"26","author":"Molina","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"suppl 1","key":"10.1016\/j.nucmedbio.2010.02.009_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","article-title":"Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer","volume":"11","author":"Baselga","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib5","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib6","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","article-title":"HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/bjc.1994.303","article-title":"The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma","volume":"70","author":"Rasbridge","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/17425247.3.1.53","article-title":"Tailoring antibodies for radionuclide delivery","volume":"3","author":"Kenanova","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib9","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2174\/138161208786404290","article-title":"Imaging of HER-2 overexpression in tumors for guiding therapy","volume":"14","author":"Tolmachev","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib10","first-page":"21","article-title":"Update on Affibody molecules for in vivo imaging of targets for cancer therapy","volume":"21","author":"Tolmachev","year":"2009","journal-title":"Minerva Biotecnol"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib11","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding Affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/bc700307y","article-title":"Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules","volume":"19","author":"Ahlgren","year":"2008","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11307-009-0238-8","article-title":"Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody molecule for targeting of HER2-expressing tumors","volume":"12","author":"W\u00e5llberg","year":"2010","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2967\/jnumed.108.056929","article-title":"Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine","volume":"50","author":"Ahlgren","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1021\/bc060291m","article-title":"In vivo evaluation of cysteine-based chelators for attachment of\u00a099mTc to tumor-targeting Affibody molecules","volume":"18","author":"Tran","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib16","first-page":"1722","article-title":"Technical problems associated with the production of technetium Tc 99m tin(II) pyrophosphate kits","volume":"38","author":"Kowalsky","year":"1981","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib17","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/jps.20148","article-title":"Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis","volume":"93","author":"Guggenberg","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib18","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1158\/0008-5472.CAN-06-2887","article-title":"Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2 expressing malignant tumors","volume":"67","author":"Orlova","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.02.009_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002590050216","article-title":"Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations","volume":"25","author":"Behr","year":"1998","journal-title":"Eur J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511000034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511000034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T01:08:54Z","timestamp":1559005734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511000034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S096980511000034X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.02.009","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}